Results 1 to 10 of about 2,934,766 (329)

Differential effects of HDAC inhibitors in the Rho I255d mouse model for autosomal dominant retinitis pigmentosa [PDF]

Cell Death Discovery
Retinitis Pigmentosa (RP) is an inherited neurodegenerative disease which leads to loss of retinal photoreceptors and blindness. Histone deacetylases (HDAC) were previously found to be involved in photoreceptor cell death, and HDAC inhibitors have shown ...
Yu Zhu, Pranav Nanda Kumar, Kangwei Jiao, François Paquet-Durand   +3 more
doaj   +2 more sources

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

Protein & Cell, 2020
Immunotherapy has been applied successfully to treat B-cell lymphomas in preclinical models or clinical settings. However, immunotherapy resistance is a major challenge for B-cell lymphoma treatment.
Xiaoguang Wang, Brittany C. Waschke, Rachel A Woolaver, Samantha M. Y. Chen, Zhangguo Chen, Jing H. Wang   +5 more
doaj   +2 more sources

Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy [PDF]

Cells
Histone deacetylases (HDACs) are pivotal epigenetic regulators that control gene expression, cell proliferation, and differentiation, and their dysregulation is closely associated with the onset and progression of multiple cancers.
Mohammed Hawash
doaj   +2 more sources

Recent Update of HDAC Inhibitors in Lymphoma

Frontiers in Cell and Developmental Biology, 2020
Modulating epigenetic modification has been recognized for over a decade as an effective therapeutic approach to cancer and many studies of histone deacetylase (HDAC), one of the best known epigenetic modulators, have been published.
I-Chung Chen, Bidyadhar Sethy, Jing-Ping Liou   +2 more
doaj   +2 more sources

Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir [PDF]

mBio
The HIV reservoir is more dynamic than previously thought with around 70% of the latent reservoir originating from viruses circulating within 1 year of the initiation of antiretroviral therapy (ART).
Lijun Ling, Manse Kim, Andrew Soper, Martina Kovarova, Rae Ann Spagnuolo, Nurjahan Begum, Jennifer Kirchherr, Nancie Archin, Diana Battaglia, Dave Cleveland, Angela Wahl, David M. Margolis, Edward P. Browne, J. Victor Garcia   +13 more
doaj   +2 more sources

Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils [PDF]

Journal of Inflammation, 2010
Background Granulocytes are important in the pathogenesis of several inflammatory diseases. Apoptosis is pivotal in the resolution of inflammation. Apoptosis in malignant cells is induced by histone deacetylase (HDAC) inhibitors, whereas HDAC inhibitors ...
Adcock Ian M, Ito Misako, Jalonen Ulla, Ito Kazuhiro, Ilmarinen-Salo Pinja, Janka-Junttila Mirkka, Kankaanranta Hannu, Moilanen Eeva, Zhang Xianzhi   +8 more
doaj   +5 more sources

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies [PDF]

European Journal of Medical Research
Histone deacetylation represents a significant epigenetic mechanism that involves the removal of acetyl groups from histones, subsequently influencing gene transcription.
Wanli Zhang, Luqi Ge, Yiwen Zhang, Zhentao Zhang, Wen Zhang, Feifeng Song, Ping Huang, Tong Xu   +7 more
doaj   +2 more sources

Recent developments of HDAC inhibitors: Emerging indications and novel molecules

British Journal of Clinical Pharmacology, 2021
The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically well established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a high number of clinical trials ...
Andrey D. Bondarev, Misty M. Attwood, Jörgen Jonsson, V. Chubarev, V. Tarasov, H. Schiöth   +5 more
semanticscholar   +1 more source

DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors in vitro

Frontiers in Genetics, 2022
Cutaneous T-cell lymphomas (CTCLs) are a subset of T-cell malignancies presenting in the skin. The treatment options for CTCL, in particular in advanced stages, are limited.
Eliza Mari Kwesi-Maliepaard, Muddassir Malik, Tibor van Welsem, Remco van Doorn, Maarten H. Vermeer, Hanneke Vlaming, Heinz Jacobs, Fred van Leeuwen, Fred van Leeuwen   +8 more
doaj   +1 more source

Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation

Pharmaceutics, 2022
Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors.
Dusan Ruzic, Bernhard Ellinger, Nemanja Djokovic, Juan F. Santibanez, Sheraz Gul, Milan Beljkas, Ana Djuric, Arasu Ganesan, Aleksandar Pavic, Tatjana Srdic-Rajic, Milos Petkovic, Katarina Nikolic   +11 more
doaj   +1 more source